DDInter1934 DDInter1435
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vilanterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Carvedilol
Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Vilanterol may lead to a major life threatening interaction when taken with Macimorelin
Vilanterol may lead to a major life threatening interaction when taken with Carvedilol